Fulcrum Therapeutics Inc.
- Address
- 26 Landsdowne Street
Sponsor Overview
Specializations
Facioscapulohumeral Muscular Dystrophy
Fulcrum Therapeutics Inc. focuses on clinical research in facioscapulohumeral muscular dystrophy, with studies centered on disease progression, muscle function, and long-term treatment effects in affected individuals.
- FSHD
- Muscle weakness
- Functional outcomes
The company’s research activity in this area is directed toward understanding and addressing the clinical burden of this inherited neuromuscular disorder.
FSHD1
Clinical trials also concentrate on FSHD1, examining safety, tolerability, and sustained treatment use in this genetic subtype of facioscapulohumeral muscular dystrophy.
- Genetic muscle disease
- Long-term tolerability
- Subtype-specific research
This area reflects a targeted interest in the clinical management of patients with the most common form of the disorder.
Neuromuscular disease assessment
The sponsor’s studies include evaluation of clinical outcome measures relevant to muscle performance, physical impairment, and progression of neuromuscular disease.
- Muscle performance
- Disease progression
- Patient function
These research efforts support a detailed focus on measurable changes in strength and daily physical capability.
Long-term safety and tolerability
Fulcrum Therapeutics maintains a research interest in the extended use of treatments for FSHD and FSHD1, with emphasis on ongoing safety monitoring and treatment tolerability.
- Safety monitoring
- Treatment tolerability
- Extended treatment use
This domain is closely tied to chronic disease care, where sustained management is central to clinical research priorities.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety Evaluation of Losmapimod in Patients with Facioscapulohumeral Muscular Dystrophy: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study |  France Spain | Not Recruiting |
| Evaluation of Losmapimod's Safety, Tolerability, and Biomarker Impact in Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) Patients |  The Netherlands | Not Recruiting |
| Phase 3 Randomized Double-Blind Placebo-Controlled Study on Losmapimod Efficacy and Safety in Facioscapulohumeral Muscular Dystrophy Patients |  Denmark France Germany Italy Spain The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 16 sites across their trial portfolio.
Therapeutic Focus
- 1.Musculoskeletal Diseases3 trials238 other sponsors
- 2.Nervous System Diseases2 trials449 other sponsors
Partnered Research Centres
16 centres- Address
- Palle Juul-Jensens Boulevard 99, 8200 Aarhus
- Address
- 151 Route De Saint Antoine, 06200 Nice
- Address
- Piazza Dell'ospedale Maggiore 3, 20162 Milan
- Address
- Via Giacomo Venezian 1, 20133 Milan
- Address
- 100 Boulevard Du General Leclerc, 92110 Clichy
- Address
- Carrer De San Quinti 89, 08041 Barcelona
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Fulcrum Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.